Alemtuzumab in solid organ transplantation and in composite tissue allotransplantation

Immunotherapy

Volumn 2, Issue 6, 2010, Pages 783-790

  Weissenbacher, Annemarie ^a   Boesmueller, Claudia ^a   Brandacher, Gerald ^a   Oellinger, Robert ^a   Pratschke, Johann ^a   Schneeberger, Stefan ^a,b  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

transplantation

Indexed keywords

ALEMTUZUMAB; BASILIXIMAB; DACLIZUMAB; METHYLPREDNISOLONE; TACROLIMUS; THYMOCYTE ANTIBODY;

ACUTE GRAFT REJECTION; ALLOTRANSPLANTATION; CARDIAC GRAFT REJECTION; CLINICAL TRIAL; CYTOMEGALOVIRUS INFECTION; DRUG EFFICACY; FOLLOW UP; GRAFT INFECTION; GRAFT RECIPIENT; HEART LUNG TRANSPLANTATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INTESTINE TRANSPLANTATION; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; LUNG GRAFT REJECTION; LYMPHOCYTOPENIA; PANCREAS TRANSPLANTATION; PRIORITY JOURNAL; REVIEW; WORK EXPERIENCE;

ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; ANTIGENS, CD; ANTIGENS, NEOPLASM; GLYCOPROTEINS; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; ORGAN TRANSPLANTATION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TISSUE TRANSPLANTATION; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 78649501213     PISSN: 1750743X     EISSN: None     Source Type: Journal    
DOI: 10.2217/imt.10.68     Document Type: Review

References (44)

1. Calne R, Moffatt SD, Friend PJ et al.: Campath 1H allows low-dose cyclosporine monotherapy in 31 cadaveric renal allograft recipients. Transplantation 68, 1613-1616 (1999).
2. Calne R, Friend P, Moffatt S et al.: Prope tolerance, perioperative campath 1H, and low-dose cyclosporin monotherapy in renal allograft recipients. Lancet 351, 1701-1702 (1998).
3. Calne R: 'Prope' tolerance: Induction, lymphocyte depletion with minimal maintenance. Transplantation 80, 6-7 (2005).
4. Kirk AD, Mannon RB, Kleiner DE et al.: Results from a human renal allograft tolerance trial evaluating T cell depletion with alemtuzumab combined with deoxyspergualin. Transplantation 80, 1051-1059 (2005).
5. Kirk AD, Hale DA, Mannon RB et al.: Results from a human renal allograft tolerance trial evaluating the humanized CD52-specific monoclonal antibody alemtuzumab (CAMPATH-1H). Transplantation 76, 120-129 (2003).
6. Tzakis AG, Kato T, Nishida S et al.: Preliminary experience with campath 1H (C1H) in intestinal and liver transplantation. Transplantation 75, 1227-1231 (2003).
7. Tzakis AG, Kato T, Nishida S et al.: Alemtuzumab (Campath-1H) combined with tacrolimus in intestinal and multivisceral transplantation. Transplantation 75, 1512-1517 (2003).
8. Tzakis AG, Tryphonopoulos P, Kato T et al.: Preliminary experience with alemtuzumab (Campath-1H) and low-dose tacrolimus immunosuppression in adult liver transplantation. Transplantation 77, 1209-1214 (2004).
9. Ciancio G, Burke GW, Gaynor JJ et al.: The use of Campath-1H induction therapy in renal transplantation: Preliminary results. Transplantation 78, 426-433 (2004).
10. Shapiro R, Basu A, Tan H et al.: Kidney transplantation under minimal immunosuppression after pretransplant lymphoid depletion with Thymoglobulin or Campath. J. Am. Coll. Surg. 200, 505-515 (2005).
11. Tzakis AG, Kato T, Nishida S et al.: Campath-1H in intestinal and multivisceral transplantation: Preliminary data. Transplant Proc. 34, 937 (2002).
12. Ciancio G, Burke GW, Gaynor JJ et al.: A randomized trial of three renal transplant induction antibodies: Early comparison of tacrolimus, mycophenolate mofetil, and steroid dosing, and newer immunemonitoring. Transplantation 80, 457 (2005).
13. Vathsala A, Ona ET, Tan SY et al.: Randomized trial of alemtuzumab for prevention of graft rejection and preservation of renal function after kidney transplantation. Transplantation 80, 765 (2005).
14. Margreiter R, Klempnauer J, Neuhaus P et al.: Alemtuzumab (Campath-1H) and tacrolimus monotherapy after renal transplantation: Results of a prospective randomized trial. Am. J. Transplant. 8, 1480-1485 (2008).
15. Shapiro R, Basu A, Tan HP et al.: Kidney after nonrenal transplantation - the impact of alemtuzumab induction. Transplantation 88, 799-802 (2009).
16. Friend PJ, Hale G, Waldmann H et al.: Campath-1M prophylactic use after kidney transplantation. A randomized controlled clinical trial. Transplantation 48, 248-253 (1989).
17. Morris PJ, Russell NK: Alemtuzumab (Campath-1H): A systematic review in organ transplantation. Transplantation 81, 1361-1367 (2006).
18. Kaufman DB, Leventhal JR, Gallon LG, Parker MA: Alemtuzumab induction and prednisone-free maintenance immunotherapy in simultaneous pancreaskidney transplantation comparison with rabbit antithymocyte globulin induction - long-term results. Am. J. Transplant. 6, 331-339 (2006).
19. Gruessner RW, Kandaswamy R, Humar A et al.: Calcineurin inhibitorand steroid-free immunosuppression in pancreas-kidney and solitary pancreas transplantation. Transplantation 79, 1184-1189 (2005).
20. Muthusamya AS, Vaidyaa AC, Sinhaa S et al.: Alemtuzumab induction and steroid-free maintenance immunosuppression in pancreas transplantation. Am. J. Transplant. 8, 2126-2131 (2008).
21. Farney AC, Doares W, Rogers J et al.: A randomized trial of alemtuzumab versus antithymocyte globulin induction in renal and pancreas transplantation. Transplantation 88, 810-819 (2009).
22. Marcos A, Eghtesad B, Fung JJ et al.: Use of alemtuzumab and tacrolimus monotherapy for cadaveric liver transplantation: With particular reference to hepatitis C virus. Transplantation 78, 966-971 (2004).
23. Kato T, Selvaggi G, Panagiotis T et al.: Pediatric liver transplant with Campath 1H induction - preliminary report. Transplant Proc. 38, 3609-3611 (2006).
24. Garcia M, Weppler D, Mittal N et al.: Campath-1H immunosuppressive therapy reduces incidence and intensity of acute rejection in intestinal and multivisceral transplantation. Transplant Proc. 36, 323-324 (2004).
25. Abu-Elmagd KM, Costa G, Bond GJ et al.: Five hundred intestinal and multivisceral transplantations at a single center: Major advances with new challenges. Ann. Surg. DOI: 10.1097/SLA.0b013e3181b67725 (2009) (Epub ahead of print).
26. Reams BD, Musselwhite LW, Zaas DW et al.: Alemtuzumab in the treatment of refractory acute rejection and bronchiolitis obliterans syndrome after human lung transplantation. Am. J. Transplant. 7, 2802-2808 (2007).
27. McCurry KR, Iacono A, Zeevi A et al.: Early outcomes in human lung transplantation with Thymoglobulin or Campath-1H for recipient pretreatment followed by posttransplant tacrolimus near-monotherapy. J. Thorac. Cardiovasc. Surg. 130, 528-537 (2005).
28. Van Loenhout KC, Groves SC, Galazka M et al.: Early outcomes using alemtuzumab induction in lung transplantation. Interact. Cardio. Vasc. Thorac. Surg. 10, 190-194 (2010).
29. Das B, Shoemaker L, Recto M, Austin E, Dowling R: Alemtuzumab (Campath-1H) induction in a pediatric heart transplant: Successful outcome and rationale for its use. J. Heart Lung Transplant. 27, 242-244 (2008).
30. Woodside KJ, Lick SD: Alemtuzumab (Campath 1H) as successful salvage therapy for recurrent steroid-resistant heart transplant rejection. J. Heart Lung Transplant. 26, 750-752 (2007).
31. Schneeberger S, Gorantla VS, van Riet RP et al.: Atypical acute rejection after hand transplantation. Am. J. Transplant. 8, 688 (2008).
32. Schneeberger S, Landin L, Kaufmann D et al.: Alemtuzumab: Key for minimization of maintenance immunosuppression in reconstrucive transplantation. Transplantation Proc. 41, 499-502 (2009).
33. Levi DM, Tzakis AG, Kato T et al.: Transplantation of the abdominal wall. Lancet 361, 2173-2175 (2003).
34. Waldmann H: A personal history of the CAMPATH-1H antibody. Med. Oncol. 19(Suppl.), S3-S9 (2002).
35. Stuart FP, Leventhal JR, Kaufman DB: Alemtuzumab facilitates prednisone free immunosuppression in kidney transplant recipients with no early rejection. Am. J. Transplant. 2, 397 (2002).
36. Knechtle SJ, Pirsch JD, Fechner J et al.: Campath-1H induction plus rapamycin monotherapy for renal transplantation: Results of a pilot study. Am. J. Transplant. 3, 722 (2003).
37. Watson CJ, Bradley JA, Friend PJ et al.: Alemtuzumab (Campath 1H) induction therapy in cadaveric kidney transplantationefficacy and safety at five years. Am. J. Transplant. 5, 1347-1353 (2005).
38. Tan HP, Donaldson J, Basu A et al.: Two hundred living donor kidney transplantations under alemtuzumab induction and tacrolimus monotherapy: 3-year follow up. Am. J. Transplant. 9, 355-366 (2009).
39. Safdar N, Smith J, Knasinski V et al.: Infections after the use of alemtuzumab in solid organ transplant recipients: A comparative study. Diagn. Microbiol. Infect. Dis. 66, 7-15 (2010).
40. Muzaffar M, Taj A, Ratnam S: Aggressive posttransplant lymphoproliferative disease in a renal transplant patient treated with alemtuzumab. Am. J. Ther. DOI: 10.1097/ MJT.0b013e3181c08042 (2009) (Epub ahead of print).
41. Magliocca JF, Odorico JS, Pirsch JD et al.: A comparison of alemtuzumab with basiliximab induction in simultaneous pancreas-kidney transplantation. Am. J. Transplant. 8, 1702-1710 (2008).
42. Silveira FP, Marcos A, Kwak EJ et al.: Bloodstream infections in organ transplant recipients receiving alemtuzumab: No evidence of occurrence of organisms typically associated with profound T cell depletetion. J. Infect. 53, 241-247 (2006).
43. Malek SK, Obmann MA, Gotoff RA et al.: Campath-1H inductin and the incidence of infectious complications in adult renal transplantation. Transplantation 81, 17 (2006).
44. Knechtle SJ: Present experience with Campath-1H in organ transplantation and its potential use in pediatric recipients. Pediatr. Transplant. 8, 106 (2004).